Millennium's Vision Thing
Executive SummaryMillennium's purchase of Leukosite appears to be a significant step towards its oft-stated goal of building a fully integrated pharmaceutical company. But some of the company's investors reacted less enthusiastically as stock prices tumbled immediately after the deal. Since then, the company's share price has almost returned to pre-deal levels. And Millennium's management says that it will reap tremendous benefits as the result of acquiring Leukosite's pipeline and late-stage clinical development capabilities,
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.